RU2009146125A - Способы снижения числа эозинофилов - Google Patents
Способы снижения числа эозинофилов Download PDFInfo
- Publication number
- RU2009146125A RU2009146125A RU2009146125/15A RU2009146125A RU2009146125A RU 2009146125 A RU2009146125 A RU 2009146125A RU 2009146125/15 A RU2009146125/15 A RU 2009146125/15A RU 2009146125 A RU2009146125 A RU 2009146125A RU 2009146125 A RU2009146125 A RU 2009146125A
- Authority
- RU
- Russia
- Prior art keywords
- eosinophils
- antibodies
- approximately
- decrease
- administration
- Prior art date
Links
- 210000003979 eosinophil Anatomy 0.000 title claims abstract 24
- 238000000034 method Methods 0.000 claims abstract 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract 4
- 238000006467 substitution reaction Methods 0.000 claims abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract 2
- 102000018358 immunoglobulin Human genes 0.000 claims abstract 2
- 230000002441 reversible effect Effects 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000003651 basophil Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
1. Способ снижения числа эозинофилов в организме человека, заключающийся в том, что указанному субъекту вводят парентерально от приблизительно 0,001 до приблизительно 100 мг/кг моноклонального, гибридного, гуманизированного антитела или антитела человека, которое связывается с ИЛ-5Р и включает Fc-фрагмент иммуноглобулина, и которое: ! а) содержит меньшее количество остатков фукозы, ! б) не содержит фукозы, или ! в) содержит замены аминокислот в виде вставок следующих аминокислотных последовательностей в Fc-фрагменте: 332Е, 239D и 330L, обозначенных индексом EU по Кабату. ! 2. Способ по п.1, где указанные антитела специфично связываются с α-цепью ИЛ-5Р. ! 3. Способ по п.1, где снижение числа эозинофилов происходит в течение первых 48 ч после введения. ! 4. Способ по п.1, где снижение числа эозинофилов является обратимым. ! 5. Способ по п.1, где число эозинофилов снижается до менее чем 50 эозинофилов/мм3. ! 6. Способ по п.1, где снижение абсолютного числа эозинофилов после введения составляет по меньшей мере приблизительно 25, по меньшей мере приблизительно 50, по меньшей мере приблизительно 75, по меньшей мере приблизительно 100, по меньшей мере приблизительно 125, по меньшей мере приблизительно 150, по меньшей мере приблизительно 175, по меньшей мере приблизительно 200, по меньшей мере приблизительно 225, по меньшей мере приблизительно 250, по меньшей мере приблизительно 275, по меньшей мере приблизительно 300, по меньшей мере приблизительно 325, по меньшей мере приблизительно 350, по меньшей мере приблизительно 375, по меньшей мере приблизительно 400, по меньшей мере приблизительно 425, по меньшей мере приблизительно 450, по меньшей мере приблизительно 475 или по меньш�
Claims (20)
1. Способ снижения числа эозинофилов в организме человека, заключающийся в том, что указанному субъекту вводят парентерально от приблизительно 0,001 до приблизительно 100 мг/кг моноклонального, гибридного, гуманизированного антитела или антитела человека, которое связывается с ИЛ-5Р и включает Fc-фрагмент иммуноглобулина, и которое:
а) содержит меньшее количество остатков фукозы,
б) не содержит фукозы, или
в) содержит замены аминокислот в виде вставок следующих аминокислотных последовательностей в Fc-фрагменте: 332Е, 239D и 330L, обозначенных индексом EU по Кабату.
2. Способ по п.1, где указанные антитела специфично связываются с α-цепью ИЛ-5Р.
3. Способ по п.1, где снижение числа эозинофилов происходит в течение первых 48 ч после введения.
4. Способ по п.1, где снижение числа эозинофилов является обратимым.
5. Способ по п.1, где число эозинофилов снижается до менее чем 50 эозинофилов/мм3.
6. Способ по п.1, где снижение абсолютного числа эозинофилов после введения составляет по меньшей мере приблизительно 25, по меньшей мере приблизительно 50, по меньшей мере приблизительно 75, по меньшей мере приблизительно 100, по меньшей мере приблизительно 125, по меньшей мере приблизительно 150, по меньшей мере приблизительно 175, по меньшей мере приблизительно 200, по меньшей мере приблизительно 225, по меньшей мере приблизительно 250, по меньшей мере приблизительно 275, по меньшей мере приблизительно 300, по меньшей мере приблизительно 325, по меньшей мере приблизительно 350, по меньшей мере приблизительно 375, по меньшей мере приблизительно 400, по меньшей мере приблизительно 425, по меньшей мере приблизительно 450, по меньшей мере приблизительно 475 или по меньшей мере приблизительно 500 эозинофилов/мм3.
7. Способ по п.1, где снижение абсолютного числа эозинофилов после введения составляет приблизительно от и включительно 50 до приблизительно 500 эозинофилов/мм3.
8. Способ по п.1, где абсолютное содержание эозинофилов после введения составляет менее приблизительно 100, менее приблизительно 75, менее приблизительно 50 или менее приблизительно 25 эозинофилов/мм3.
9. Способ по п.1, где абсолютное содержание эозинофилов у субъекта до введения составляет от приблизительно 50 до приблизительно 500 эозинофилов/мм3.
10. Способ по любому из пп.1-9, где абсолютное число эозинофилов у субъекта до введения составляет приблизительно 25, приблизительно 50, приблизительно 75, приблизительно 100, приблизительно 125, приблизительно 150, приблизительно 175, приблизительно 200, приблизительно 225, приблизительно 250, приблизительно 275, приблизительно 300, приблизительно 325, приблизительно 350, приблизительно 375, приблизительно 400, приблизительно 450, приблизительно 475 или приблизительно 500 эозинофилов/мм3.
11. Способ по п.1, где абсолютное число базофилов у субъекта снижается после введения по меньшей мере на приблизительно 5, по меньшей мере на приблизительно 10, по меньшей мере на приблизительно 15, по меньшей мере на приблизительно 20, по меньшей мере на приблизительно 25, по меньшей мере на приблизительно 30, по меньшей мере на приблизительно 35, по меньшей мере на приблизительно 40, по меньшей мере на приблизительно 45, по меньшей мере на приблизительно 50, по меньшей мере на приблизительно 55, по меньшей мере на приблизительно 60, по меньшей мере на приблизительно 65, по меньшей мере на приблизительно 70 базофилов/мм3.
12. Способ по п.1, где указанное снижение числа эозинофилов приводит к уменьшению симптомов астмы.
13. Способ по п.1, где указанное снижение числа эозинофилов приводит к уменьшению симптомов ХОЗЛ.
14. Способ по п.1, при условии, что антитела, связывающиеся с ИЛ-5Р, не обозначают MEDI-563.
15. Выделенное антитело к ИЛ-5Р, которое связывается с тем же эпитопом, что и MEDI-563.
16. Антитела к ИЛ-5Р по п.15, где антитела связываются с эпитопом, включающим остатки 52-67 SEQ ID №5 при условии, что антитела не обозначает MEDI-563.
17. Антитела к ИЛ-5Р по п.15, где антитела связываются с первым антигеном, включающим остатки 40-67 SEQ ID №5, но не связываются со вторым антигеном, включающим вариант остатков 40-67 SEQ ID №5, где вариант включает замену 161K, при условии, что антитела не обозначают MEDI-563.
18. Антитела к ИЛ-5Р по п.15, где антитела связываются с полипептидом ИЛ-5Рα человека, включающим аминокислотную последовательность SEQ ID №5, но не связываются с мутантным полипептидом ИЛ-5Рα человека, включающим замену 161K, при условии, что антитела не обозначают MEDI-563.
19. Антитела к ИЛ-5Р по любому из пп.15-18, где антитела являются антителам человека, гуманизированными или гибридными антителами.
20. Выделенный эпитоп ИЛ-5Рα, включающий аминокислотные остатки 52-67 SEQ ID №5.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92442207P | 2007-05-14 | 2007-05-14 | |
| US60/924,422 | 2007-05-14 | ||
| US92483207P | 2007-06-01 | 2007-06-01 | |
| US60/924,832 | 2007-06-01 | ||
| US93500507P | 2007-07-20 | 2007-07-20 | |
| US60/935,005 | 2007-07-20 | ||
| US6461208P | 2008-03-14 | 2008-03-14 | |
| US61/064,612 | 2008-03-14 | ||
| PCT/US2008/006156 WO2008143878A1 (en) | 2007-05-14 | 2008-05-14 | Methods of reducing eosinophil levels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014105496A Division RU2618455C2 (ru) | 2007-05-14 | 2014-02-14 | Способы снижения числа базофилов |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009146125A true RU2009146125A (ru) | 2011-06-20 |
| RU2519227C2 RU2519227C2 (ru) | 2014-06-10 |
Family
ID=40122040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009146125/15A RU2519227C2 (ru) | 2007-05-14 | 2008-05-14 | Способы снижения числа эозинофилов |
| RU2014105496A RU2618455C2 (ru) | 2007-05-14 | 2014-02-14 | Способы снижения числа базофилов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014105496A RU2618455C2 (ru) | 2007-05-14 | 2014-02-14 | Способы снижения числа базофилов |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20100291073A1 (ru) |
| EP (2) | EP2068927B1 (ru) |
| JP (7) | JP2010527356A (ru) |
| KR (3) | KR101588061B1 (ru) |
| CN (2) | CN101848732B (ru) |
| AU (3) | AU2008255027B2 (ru) |
| BR (1) | BRPI0811526A2 (ru) |
| CA (2) | CA2685222C (ru) |
| CY (2) | CY1117594T1 (ru) |
| DK (2) | DK3072525T3 (ru) |
| ES (2) | ES2558689T3 (ru) |
| HR (2) | HRP20160058T1 (ru) |
| HU (2) | HUE036885T2 (ru) |
| IL (2) | IL202102A (ru) |
| LT (1) | LT3072525T (ru) |
| MX (3) | MX376656B (ru) |
| NO (1) | NO3072525T3 (ru) |
| NZ (2) | NZ741494A (ru) |
| PL (2) | PL2068927T3 (ru) |
| PT (2) | PT2068927E (ru) |
| RU (2) | RU2519227C2 (ru) |
| SG (2) | SG10202000728UA (ru) |
| SI (2) | SI2068927T1 (ru) |
| WO (1) | WO2008143878A1 (ru) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008113056A2 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| DK3072525T3 (en) * | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| CN102186350A (zh) | 2008-08-19 | 2011-09-14 | 诺普神经科学股份有限公司 | 使用(r)-普拉克索的组合物与方法 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US8961965B2 (en) * | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US20140328839A1 (en) * | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| SMT202100119T1 (it) | 2013-07-12 | 2021-05-07 | Knopp Biosciences Llc | Trattamento dei livelli elevati di eosinofili e/o basofili |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| WO2015023504A1 (en) * | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| KR102337599B1 (ko) * | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 |
| MX368474B (es) * | 2013-08-12 | 2019-10-04 | Astrazeneca Ab | Uso de benralizumab para mejorar síntomas de asma. |
| AU2014306597B2 (en) | 2013-08-13 | 2018-05-17 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
| EP3038467B1 (en) | 2013-08-13 | 2020-07-29 | Knopp Biosciences LLC | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
| RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| CN106659782B (zh) * | 2014-05-23 | 2021-11-09 | 塞尔德克斯医疗公司 | 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体 |
| AU2016272399B2 (en) * | 2015-06-01 | 2021-09-09 | Kyowa Kirin Co., Ltd. | Therapeutic agent and therapeutic method for pulmonary hypertension |
| JP2018538249A (ja) | 2015-11-04 | 2018-12-27 | アストラゼネカ アクチボラグ | 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业（上海）股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
| EP3732194A1 (en) * | 2017-12-29 | 2020-11-04 | Cornell University | Gene therapy for eosinophilic disorders |
| JP2021535100A (ja) | 2018-08-24 | 2021-12-16 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | Ｍ２マクロファージ極性化を調節する方法及び治療におけるその使用 |
| TW202110479A (zh) | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| TW202214692A (zh) | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| KR102697770B1 (ko) * | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인간 IL-5Rα에 결합하는 항체 및 이의 용도 |
| CA3204307A1 (en) | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | Anti-il5r antibody formulations |
| AU2022349077A1 (en) * | 2021-09-22 | 2024-03-28 | Sonoma Biotherapeutics, Inc. | Il5ra cell surface markers |
| CN115671140B (zh) * | 2022-10-31 | 2024-03-22 | 华中科技大学同济医学院附属同济医院 | 丙酸痤疮杆菌在制备治疗鼻息肉的药品中的应用 |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633187A (en) | 1898-12-20 | 1899-09-19 | Alba L Holmes | Meter-box. |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| WO1992019973A1 (en) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6465616B1 (en) | 1994-04-08 | 2002-10-15 | Bresagen Limited | Interleukin-5 antagonist |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| AU3382595A (en) | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5677280A (en) | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
| US6018032A (en) * | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| US7033840B1 (en) * | 1999-11-09 | 2006-04-25 | Sri International | Reaction calorimeter and differential scanning calorimeter for the high-throughput synthesis, screening and characterization of combinatorial libraries |
| ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
| US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
| CA2402477A1 (en) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU5345901A (en) | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| US20060257399A1 (en) | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
| KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
| US7632983B2 (en) | 2000-07-31 | 2009-12-15 | Biolex Therapeutics, Inc. | Expression of monoclonal antibodies in duckweed |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| JP2005500018A (ja) | 2001-04-02 | 2005-01-06 | アイデック ファーマスーティカルズ コーポレイション | ＧｎＴＩＩＩと同時発現する組換え抗体 |
| CA2455365C (en) | 2001-08-03 | 2014-07-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| ES2362419T3 (es) | 2002-04-09 | 2011-07-05 | Kyowa Hakko Kirin Co., Ltd. | Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa. |
| CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US20060147523A1 (en) * | 2002-10-16 | 2006-07-06 | Alan Fergusson | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US20070148170A1 (en) * | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| AU2004279740A1 (en) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition specifically binding to IL-5 receptor |
| US20050226867A1 (en) | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
| US20050095602A1 (en) * | 2003-11-04 | 2005-05-05 | West Jason A. | Microfluidic integrated microarrays for biological detection |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| BRPI0510674A (pt) * | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
| AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006071280A1 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform |
| WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| DK1945665T3 (da) | 2005-10-21 | 2012-02-06 | Genzyme Corp | Antistof-baserede terapimidler med forhøjet ADCC-aktivitet |
| DK3072525T3 (en) * | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
-
2008
- 2008-05-14 DK DK15190653.4T patent/DK3072525T3/en active
- 2008-05-14 HU HUE15190653A patent/HUE036885T2/hu unknown
- 2008-05-14 CN CN2008800233678A patent/CN101848732B/zh active Active
- 2008-05-14 NZ NZ741494A patent/NZ741494A/en unknown
- 2008-05-14 NZ NZ599278A patent/NZ599278A/en unknown
- 2008-05-14 WO PCT/US2008/006156 patent/WO2008143878A1/en not_active Ceased
- 2008-05-14 BR BRPI0811526A patent/BRPI0811526A2/pt not_active Application Discontinuation
- 2008-05-14 ES ES08779619.9T patent/ES2558689T3/es active Active
- 2008-05-14 NO NO15190653A patent/NO3072525T3/no unknown
- 2008-05-14 DK DK08779619.9T patent/DK2068927T3/da active
- 2008-05-14 MX MX2015011174A patent/MX376656B/es active IP Right Grant
- 2008-05-14 MX MX2020011303A patent/MX388895B/es unknown
- 2008-05-14 KR KR1020097025886A patent/KR101588061B1/ko active Active
- 2008-05-14 EP EP08779619.9A patent/EP2068927B1/en active Active
- 2008-05-14 CA CA2685222A patent/CA2685222C/en active Active
- 2008-05-14 SI SI200831561A patent/SI2068927T1/sl unknown
- 2008-05-14 PT PT87796199T patent/PT2068927E/pt unknown
- 2008-05-14 JP JP2010508412A patent/JP2010527356A/ja active Pending
- 2008-05-14 SG SG10202000728UA patent/SG10202000728UA/en unknown
- 2008-05-14 KR KR1020157023657A patent/KR20150107890A/ko not_active Withdrawn
- 2008-05-14 ES ES15190653.4T patent/ES2666165T3/es active Active
- 2008-05-14 SI SI200831949T patent/SI3072525T1/en unknown
- 2008-05-14 AU AU2008255027A patent/AU2008255027B2/en active Active
- 2008-05-14 SG SG10201503254TA patent/SG10201503254TA/en unknown
- 2008-05-14 KR KR1020167000810A patent/KR101827179B1/ko active Active
- 2008-05-14 RU RU2009146125/15A patent/RU2519227C2/ru active
- 2008-05-14 CA CA2986531A patent/CA2986531C/en active Active
- 2008-05-14 PL PL08779619T patent/PL2068927T3/pl unknown
- 2008-05-14 LT LTEP15190653.4T patent/LT3072525T/lt unknown
- 2008-05-14 HR HRP20160058TT patent/HRP20160058T1/hr unknown
- 2008-05-14 PT PT151906534T patent/PT3072525T/pt unknown
- 2008-05-14 US US12/600,017 patent/US20100291073A1/en not_active Abandoned
- 2008-05-14 PL PL15190653T patent/PL3072525T3/pl unknown
- 2008-05-14 HU HUE08779619A patent/HUE026728T2/en unknown
- 2008-05-14 MX MX2009012341A patent/MX2009012341A/es active IP Right Grant
- 2008-05-14 CN CN201310170361.6A patent/CN103223167B/zh active Active
- 2008-05-14 EP EP15190653.4A patent/EP3072525B1/en active Active
-
2009
- 2009-11-12 IL IL202102A patent/IL202102A/en active IP Right Grant
-
2011
- 2011-07-06 US US13/177,221 patent/US8501176B2/en active Active
-
2013
- 2013-07-03 US US13/934,271 patent/US9815895B2/en active Active
- 2013-12-20 AU AU2013273774A patent/AU2013273774B2/en active Active
-
2014
- 2014-02-14 RU RU2014105496A patent/RU2618455C2/ru active
-
2015
- 2015-07-27 IL IL240179A patent/IL240179B/en active IP Right Grant
- 2015-07-31 JP JP2015151502A patent/JP2016034940A/ja active Pending
-
2016
- 2016-01-20 CY CY20161100052T patent/CY1117594T1/el unknown
- 2016-12-12 AU AU2016273830A patent/AU2016273830B2/en active Active
-
2017
- 2017-07-12 JP JP2017135920A patent/JP2018021017A/ja active Pending
-
2018
- 2018-04-17 HR HRP20180611TT patent/HRP20180611T1/hr unknown
- 2018-04-27 CY CY20181100445T patent/CY1120417T1/el unknown
-
2019
- 2019-07-11 JP JP2019129029A patent/JP2019194242A/ja active Pending
-
2021
- 2021-10-21 JP JP2021172302A patent/JP2022023157A/ja active Pending
-
2023
- 2023-08-24 JP JP2023136193A patent/JP2023159349A/ja active Pending
-
2025
- 2025-03-07 JP JP2025036248A patent/JP2025087854A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009146125A (ru) | Способы снижения числа эозинофилов | |
| JP2010527356A5 (ru) | ||
| EP3027650B1 (en) | Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1 | |
| US12071484B2 (en) | Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein | |
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| US20100040537A1 (en) | Prostaglandin E2 Binding Proteins and Uses Thereof | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| JP2017532037A (ja) | ヒト化抗ｏｘ４０抗体及びその使用 | |
| AU2010248935B2 (en) | Methods and compositions for treating lupus | |
| KR20120089346A (ko) | 높은 차단 활성을 갖는 항-Ｃ5ａ 결합 부분 | |
| RU2013125457A (ru) | Комбинация антител против с-мет | |
| CN102597234B (zh) | 人源化抗淀粉样-b寡聚体抗体 | |
| JP2013519690A5 (ru) | ||
| CN101880324A (zh) | 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用 | |
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| KR102753603B1 (ko) | 신규한 Nav1.7 모노클로날 항체 | |
| WO2015063228A9 (en) | Il-3 blockade in systemic lupus erythematosus and multiple sclerosis | |
| CN116003620A (zh) | 一种结合PD-1和Siglec15的双特异性抗体 | |
| KR20250169636A (ko) | 항체 또는 이의 항원-결합 단편 | |
| NZ617725B2 (en) | Antibodies against g-csfr and uses thereof | |
| HK1196384B (en) | Antibodies against g-csfr and uses thereof | |
| HK1196384A (en) | Antibodies against g-csfr and uses thereof | |
| Steele et al. | Design, Synthesis and Characterization of Conformational Peptides at the Interface of HER-2 Dimerization and Pertuzumab Binding | |
| HK1225391B (en) | Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20170330 |
|
| PD4A | Correction of name of patent owner | ||
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20190806 |
|
| PD4A | Correction of name of patent owner |